Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab)
重组抗HER2人源化HuA21单克隆抗体（瀚科迈博）
Report date: 2024/02/22 16:15:27
Base Information
Drug NameRecombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHefei Hankemab Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesHefei Hankemab Biotechnology Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A